Novel cytokine signaling pathways in inflammatory bowel disease: Insight into the dichotomous functions of IL-33 during chronic intestinal inflammation

Therapeutic Advances in Gastroenterology

Volumn 4, Issue 5, 2011, Pages 311-323

  Pastorelli, Luca ^a   De Salvo, Carlo ^a   Cominelli, Marissa A ^a   Pizarro, Theresa T ^a   Vecchi, Maurizio ^b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b IRCCS POLICLINICO SAN DONATO   (Italy)

Author keywords

Alarmins; Crohn's disease; Inflammatory bowel disease; Interleukin 33; Intestinal inflammation; Mucosal immunity; ST2; Ulcerative colitis; Wound healing

Indexed keywords

CYTOKINE; INTERLEUKIN 33; PROTEIN; PROTEIN ST2; UNCLASSIFIED DRUG;

CHRONIC INFLAMMATION; CYTOKINE PRODUCTION; ENTERITIS; HUMAN; IMMUNOPATHOGENESIS; INTESTINE LYMPHATIC TISSUE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; TH17 CELL; TH2 CELL; ULCERATIVE COLITIS;

EID: 80052370458     PISSN: 1756283X     EISSN: 17562648     Source Type: Journal    
DOI: 10.1177/1756283X11410770     Document Type: Review

References (68)

1. Ahern P.P. Izcue A. Maloy K.J. Powrie F. (2008) The interleukin-23 axis in intestinal inflammation. Immunol Rev 226: 147–159.
2. Andus, T., Daig, R., Vogl, D., Aschenbrenner, E., Lock, G., Hollerbach, S., et al. (1997) Imbalance of the interleukin 1 system in colonic mucosa–association with intestinal inflammation and interleukin 1 receptor antagonist [corrected] genotype 2. Gut 41: 651–657.
3. Artis D. (2008) Epithelial-cell recognition of commensal bacteria and maintenance of immune homeostasis in the gut. Nat Rev Immunol 8: 411–420.
4. Auron P.E. Webb A.C. Rosenwasser L.J. Mucci S.F. Rich A. Wolff S.M. et al (1984) Nucleotide sequence of human monocyte interleukin 1 precursor cDNA. Proc Natl Acad Sci U S A 81: 7907–7911.
5. Baekkevold E.S. Roussigne M. Yamanaka T. Johansen F.E. Jahnsen F.L. Amalric F. et al (2003) Molecular characterization of NF-HEV, a nuclear factor preferentially expressed in human high endothelial venules. Am J Pathol 163: 69–79.
6. Bamias G. Martin C. Mishina M. Ross W.G. Rivera-Nieves J. Marini M. et al (2005) Proinflammatory effects of TH 2 cytokines in a murine model of chronic small intestinal inflammation. Gastroenterology 128: 654–666.
7. Beltran C.J. Nunez L.E. Diaz-Jimenez D. Farfan N. Candia E. Heine C. et al (2010) Characterization of the novel ST2/IL-33 system in patients with inflammatory bowel disease. Inflamm Bowel Dis 16: 1097–1107.
8. Bulek K. Swaidani S. Qin J. Lu Y. Gulen M.F. Herjan T. et al (2009) The essential role of single Ig IL-1 receptor-related molecule/Toll IL-1R8 in regulation of Th 2 immune response. J Immunol 182: 2601–2609.
9. Casini-Raggi V. Kam L. Chong Y.J. Fiocchi C. Pizarro T.T. Cominelli F. (1995) Mucosal imbalance of IL-1 and IL-1 receptor antagonist in inflammatory bowel disease. A novel mechanism of chronic intestinal inflammation. J Immunol 154: 2434–2440.
10. Cayrol C. Girard J.P. (2009) The IL-1-like cytokine IL-33 is inactivated after maturation by caspase-1. Proc Natl Acad Sci U S A 106: 9021–9026.
11. Chen C.J. Kono H. Golenbock D. Reed G. Akira S. Rock K.L. (2007) Identification of a key pathway required for the sterile inflammatory response triggered by dying cells. Nat Med 13: 851–856.
12. Cominelli, F., Nast, C.C., Clark, B.D., Schindler, R., Lierena, R., Eysselen, V.E., et al. (1990) J Clin Invest 86: 972–980.
13. Cominelli F. Pizarro T.T. (1996) Interleukin-1 and interleukin-1 receptor antagonist in inflammatory bowel disease. Aliment Pharmacol Ther 10(Suppl. 2): 49–53; discussion 54.
14. Corbaz, A., ten Hove, T., Herren, S., Graber, P., Schwartsburd, B., Belzer, I., et al. (2002) IL-18 binding protein expression by endothelial cells and macrophages is up-regulated during active Crohn's disease. J Immunol 168: 3608–3616.
15. Dinarello C.A. (2009) Interleukin-1beta and the autoinflammatory diseases. N Engl J Med 360: 2467–2470.
16. Fagundes C.T. Amaral F.A. Souza A.L. Vieira A.T. Xu D. Liew F.Y. et al (2007) ST2, an IL-1R family member, attenuates inflammation and lethality after intestinal ischemia and reperfusion. J Leukoc Biol 81: 492–499.
17. Ferretti M. Casini-Raggi V. Pizarro T.T. Eisenberg S.P. Nast C.C. Cominelli F. (1994) Neutralization of endogenous IL-1 receptor antagonist exacerbates and prolongs inflammation in rabbit immune colitis. J Clin Invest 94: 449–453.
18. Fina D. Sarra M. Fantini M.C. Rizzo A. Caruso R. Caprioli F. et al (2008) Regulation of gut inflammation and th 17 cell response by interleukin-21. Gastroenterology 134: 1038–1048.
19. Huang X. Du W. Barrett R.P. Hazlett L.D. (2007) ST2 is essential for Th2 responsiveness and resistance to pseudomonas aeruginosa keratitis. Invest Ophthalmol Vis Sci 48: 4626–4633.
20. Humphreys N.E. Xu D. Hepworth M.R. Liew F.Y. Grencis R.K. (2008) IL-33, a potent inducer of adaptive immunity to intestinal nematodes. J Immunol 180: 2443–2449.
21. Jones L.A. Roberts F. Nickdel M.B. Brombacher F. McKenzie A.N. Henriquez F.L. et al (2010) IL-33 receptor (T1/ST2) signalling is necessary to prevent the development of encephalitis in mice infected with Toxoplasma gondii. Eur J Immunol 40: 426–436.
22. Kaser A. Zeissig S. Blumberg R.S. (2010) Inflammatory bowel disease. Annu Rev Immunol 28: 573–621.
23. Kobori A. Yagi Y. Imaeda H. Ban H. Bamba S. Tsujikawa T. et al (2010) Interleukin-33 expression is specifically enhanced in inflamed mucosa of ulcerative colitis. J Gastroenterol, in press in press.
24. Komai-Koma M. Xu D. Li Y. McKenzie A.N. McInnes I.B. Liew F.Y. (2007) IL-33 is a chemoattractant for human Th 2 cells. Eur J Immunol 37: 2779–2786.
25. Kuchler A.M. Pollheimer J. Balogh J. Sponheim J. Manley L. Sorensen D.R. et al (2008) Nuclear interleukin-33 is generally expressed in resting endothelium but rapidly lost upon angiogenic or proinflammatory activation. Am J Pathol 173: 1229–1242.
26. Kurowska-Stolarska M. Kewin P. Murphy G. Russo R.C. Stolarski B. Garcia C.C. et al (2008) IL-33 induces antigen-specific IL-5+ T cells and promotes allergic-induced airway inflammation independent of IL-4. J Immunol 181: 4780–4790.
27. Kurowska-Stolarska M. Stolarski B. Kewin P. Murphy G. Corrigan C.J. Ying S. et al (2009) IL-33 amplifies the polarization of alternatively activated macrophages that contribute to airway inflammation. J Immunol 183: 6469–6477.
28. Liew F.Y. Pitman N.I. McInnes I.B. (2010) Disease-associated functions of IL-33: the new kid in the IL-1 family. Nat Rev Immunol 10: 103–110.
29. Liu X. Li M. Wu Y. Zhou Y. Zeng L. Huang T. (2009) Anti-IL-33 antibody treatment inhibits airway inflammation in a murine model of allergic asthma. Biochem Biophys Res Commun 386: 181–185.
30. Luthi A.U. Cullen S.P. McNeela E.A. Duriez P.J. Afonina I.S. Sheridan C. et al (2009) Suppression of interleukin-33 bioactivity through proteolysis by apoptotic caspases. Immunity 31: 84–98.
31. Marillier R.G. Michels C. Smith E.M. Fick L.C. Leeto M. Dewals B. et al (2008) IL-4/IL-13 independent goblet cell hyperplasia in experimental helminth infections. BMC Immunol 9: 11–11.
32. Matsuba-Kitamura S. Yoshimoto T. Yasuda K. Futatsugi-Yumikura S. Taki Y. Muto T. et al (2010) Contribution of IL-33 to induction and augmentation of experimental allergic conjunctivitis. Int Immunol 22: 479–489.
33. Miller A.M. Xu D. Asquith D.L. Denby L. Li Y. Sattar N. et al (2008) IL-33 reduces the development of atherosclerosis. J Exp Med 205: 339–346.
34. Mitsuyama K. Matsumoto S. Rose-John S. Suzuki A. Hara T. Tomiyasu N. et al (2006) STAT3 activation via interleukin 6 trans-signalling contributes to ileitis in SAMP1/Yit mice. Gut 55: 1263–1269.
35. Monteleone G. Trapasso F. Parrello T. Biancone L. Stella A. Iuliano R. et al (1999) Bioactive IL-18 expression is up-regulated in Crohn's disease. J Immunol 163: 143–147.
36. Moro K. Yamada T. Tanabe M. Takeuchi T. Ikawa T. Kawamoto H. et al (2010) Innate production of T(H)2 cytokines by adipose tissue-associated c-Kit(+)Sca-1(+) lymphoid cells. Nature 463: 540–544.
37. Moussion C. Ortega N. Girard J.P. (2008) The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel ‘alarmin’? PloS ONE 3: e3331–e3331.
38. Murch S.H. Braegger C.P. Walker-Smith J.A. MacDonald T.T. (1993) Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease. Gut 34: 1705–1709.
39. Neill D.R. Wong S.H. Bellosi A. Flynn R.J. Daly M. Langford T.K. et al (2010) Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity. Nature 464: 1367–1370.
40. Nishiyama, T., Mitsuyama, K., Toyonaga, A., Sasaki, E. and Tanikawa, K. (1994) Colonic mucosal interleukin 1 receptor antagonist in inflammatory bowel disease. Digestion 55: 368–373.
41. O'Connor W. Jr Kamanaka M. Booth C.J. Town T. Nakae S. Iwakura Y. et al (2009) A protective function for interleukin 17A in T cell-mediated intestinal inflammation. Nature immunology 10: 603–609.
42. Oboki K. Ohno T. Kajiwara N. Arae K. Morita H. Ishii A. et al (2010) IL-33 is a crucial amplifier of innate rather than acquired immunity. Proc Natl Acad Sci U S A 107: 18581–18586.
43. Oshikawa K. Yanagisawa K. Tominaga S. Sugiyama Y. (2002) Expression and function of the ST 2 gene in a murine model of allergic airway inflammation. Clin Exp Allergy 32: 1520–1526.
44. Palmer G. Lipsky B.P. Smithgall M.D. Meininger D. Siu S. Talabot-Ayer D. et al (2008) The IL-1 receptor accessory protein (AcP) is required for IL-33 signaling and soluble AcP enhances the ability of soluble ST 2 to inhibit IL-33. Cytokine 42: 358–364.
45. Palmer G. Talabot-Ayer D. Lamacchia C. Toy D. Seemayer C.A. Viatte S. et al (2009) Inhibition of interleukin-33 signaling attenuates the severity of experimental arthritis. Arthritis Rheum 60: 738–749.
46. Pasparakis M. (2008) IKK/NF-kappaB signaling in intestinal epithelial cells controls immune homeostasis in the gut. Mucosal Immunol 1(Suppl. 1): S54–S57.
47. Pastorelli L. Garg R.R. Hoang S.B. Spina L. Mattioli B. Scarpa M. et al (2010) Epithelial-derived IL-33 and its receptor ST 2 are dysregulated in ulcerative colitis and in experimental Th1/Th2 driven enteritis. Proc Natl Acad Sci U S A 107: 8017–8022.
48. Pastorelli L. Vecchi M. Cominelli F. Pizarro T.T. (2008) Genetic regulation of epithelial barrier function: Recent insights into the pathogenesis of inflammatory bowel disease. IBD Monitor 8: 124–133.
49. Pizarro T.T. Michie M.H. Bentz M. Woraratanadharm J. Smith M.F. Jr Foley E. et al (1999) IL-18, a novel immunoregulatory cytokine, is up-regulated in Crohn's disease: expression and localization in intestinal mucosal cells. J Immunol 162: 6829–6835.
50. Price A.E. Liang H.E. Sullivan B.M. Reinhardt R.L. Eisley C.J. Erle D.J. et al (2010) Systemically dispersed innate IL-13-expressing cells in type 2 immunity. Proc Natl Acad Sci U S A 107: 11489–11494.
51. Pushparaj P.N. Tay H.K. H'Ng S.C. Pitman N. Xu D. McKenzie A. et al (2009) The cytokine interleukin-33 mediates anaphylactic shock. Proc Natl Acad Sci U S A 106: 9773–9778.
52. Reuter B.K. Pizarro T.T. (2004) Commentary: the role of the IL-18 system and other members of the IL-1R/TLR superfamily in innate mucosal immunity and the pathogenesis of inflammatory bowel disease: friend or foe? Eur J Immunol 34: 2347–2355.
53. Rivera-Nieves J. Bamias G. Vidrich A. Marini M. Pizarro T.T. McDuffie M.J. et al (2003) Emergence of perianal fistulizing disease in the SAMP1/YitFc mouse, a spontaneous model of chronic ileitis. Gastroenterology 124: 972–982.
54. Scaffidi P. Misteli T. Bianchi M.E. (2002) Release of chromatin protein HMGB 1 by necrotic cells triggers inflammation. Nature 418: 191–195.
55. Schmitz J. Owyang A. Oldham E. Song Y. Murphy E. McClanahan T.K. et al (2005) IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST 2 and induces T helper type 2-associated cytokines. Immunity 23: 479–490.
56. Seidelin J.B. Bjerrum J.T. Coskun M. Widjaya B. Vainer B. Nielsen O.H. (2010) IL-33 is upregulated in colonocytes of ulcerative colitis. Immunol Lett 128: 80–85.
57. Shimizu M. Matsuda A. Yanagisawa K. Hirota T. Akahoshi M. Inomata N. et al (2005) Functional SNPs in the distal promoter of the ST 2 gene are associated with atopic dermatitis. Hum Mol Genet 14: 2919–2927.
58. Smithgall M.D. Comeau M.R. Yoon B.R. Kaufman D. Armitage R. Smith D.E. (2008) IL-33 amplifies both Th1- and Th2-type responses through its activity on human basophils, allergen-reactive Th 2 cells, iNKT and NK cells. Int Immunol 20: 1019–1030.
59. Takedatsu H. Mitsuyama K. Matsumoto S. Handa K. Suzuki A. Funabashi H. et al (2004) Interleukin-5 participates in the pathogenesis of ileitis in SAMP1/Yit mice. Eur J Immunol 34: 1561–1569.
60. Talabot-Ayer D. Lamacchia C. Gabay C. Palmer G. (2009) Interleukin-33 is biologically active independently of caspase-1 cleavage. J Biol Chem 284: 19420–19426.
61. Verri W.A. Jr Souto F.O. Vieira S.M. Almeida S.C. Fukada S.Y. Xu D. et al (2010) IL-33 induces neutrophil migration in rheumatoid arthritis and is a target of anti-TNF therapy. Ann Rheum Dis 69: 1697–1703.
62. Wagenaar J.F. Gasem M.H. Goris M.G. Leeflang M. Hartskeerl R.A. van der Poll T. et al (2009) Soluble ST 2 levels are associated with bleeding in patients with severe Leptospirosis. PLoS Negl Trop Dis 3: e453–e453.
63. Wehkamp J. Koslowski M. Wang G. Stange E.F. (2008) Barrier dysfunction due to distinct defensin deficiencies in small intestinal and colonic Crohn's disease. Mucosal Immunol 1(Suppl. 1): S67–S74.
64. Wood I.S. Wang B. Trayhurn P. (2009) IL-33, a recently identified interleukin-1 gene family member, is expressed in human adipocytes. Biochem Biophys Res Commun 384: 105–109.
65. Xavier R.J. Podolsky D.K. (2007) Unravelling the pathogenesis of inflammatory bowel disease. Nature 448: 427–434.
66. Xu D. Jiang H.R. Kewin P. Li Y. Mu R. Fraser A.R. et al (2008) IL-33 exacerbates antigen-induced arthritis by activating mast cells. Proc Natl Acad Sci U S A 105: 10913–10918.
67. Zhang Z. Zheng M. Bindas J. Schwarzenberger P. Kolls J.K. (2006) Critical role of IL-17 receptor signaling in acute TNBS-induced colitis. Inflamm Bowel Dis 12: 382–388.
68. Zhiguang X. Wei C. Steven R. Wei D. Wei Z. Rong M. et al (2010) Over-expression of IL-33 leads to spontaneous pulmonary inflammation in mIL-33 transgenic mice. Immunol Lett 131: 159–165.